Last Updated 19:00:00 ET
longbridge loading
Company Encyclopedia
View More
name
Zeo ScientifiX, Inc.
ZEOX.US
Zeo ScientifiX, Inc., a clinical-stage biopharmaceutical company, focuses on the development of biological therapeutics for the treatment of degenerative diseases and regenerative medicines. The company’s lead product candidate is Zofin, an acellular biologic therapeutic derived from perinatal sources, which is in Phase I/II clinical trial to treat COVID-19, chronic obstructive pulmonary disease, and knee osteoarthritis. It also provides Patient Pure X, an autologous blood-derived biologic technology, that helps the body’s natural ability to decrease cellular inflammation and promote tissue healing. In addition, the company develops and distributes products that incorporate its proprietary ingredients for products to be used in topical aesthetic applications; ZEO GROW X, a professional-grade formula that delivers a concentrated dose of topical exosomes that help support follicular function; ZEO GROW BOOST; and EXO FOLLICLE FUEL.
1.880 T
ZEOX.USMarket value -Rank by Market Cap -/-

Financial Score

18/01/2026 Update
C
BiotechnologyIndustry
Industry Ranking161/398
Industry medianC
Industry averageD
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreB
    • ROE319.06%A
    • Profit Margin-124.45%E
    • Gross Margin82.54%A
  • Growth ScoreD
    • Revenue YoY-0.19%D
    • Net Profit YoY-31.22%D
    • Total Assets YoY-25.62%E
    • Net Assets YoY-62.73%E
  • Cash ScoreD
    • Cash Flow Margin-80.35%D
    • OCF YoY-0.19%D
  • Operating ScoreA
    • Turnover2.47A
  • Debt ScoreE
    • Gearing Ratio240.07%E

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --